高级检索
当前位置: 首页 > 详情页

The Role of Diverse Immune Cells in Sarcoidosis

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]China Japan Friendship Hosp, Peking Union Med Coll, Ctr Resp Med, Dept Pulm & Crit Care Med, Beijing, Peoples R China [2]Univ Hosp, Ruhrlandklin, Pneumol Dept, Ctr Interstitial & Rare Lung Dis, Essen, Germany [3]China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm & Crit Care Med, Beijing, Peoples R China [4]Natl Ctr Resp Med, Beijing, Peoples R China [5]Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China [6]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China
出处:
ISSN:

关键词: sarcoidosis Th17 cells regulatory T cells macrophages B cells dendritic cells natural killer cells

摘要:
Sarcoidosis is a systemic inflammatory disorder of unknown etiology characterized by tissue infiltration with macrophages and lymphocytes and associated non-caseating granuloma formation. The disease primarily affects the lungs. Patients suffering from sarcoidosis show a wide range of clinical symptoms, natural history and disease outcomes. Originally described as a Th1-driven disease, sarcoidosis involves a complex interplay among diverse immune cells. This review highlights recent advances in the pathogenesis of sarcoidosis, with emphasis on the role of different immune cells. Accumulative evidence suggests Th17 cells, IFN-gamma-producing Th17 cells or Th17.1 cells, and regulatory T (Treg) cells play a critical role. However, their specific actions, whether protective or pathogenic, remain to be clarified. Macrophages are also involved in granuloma formation, and M2 polarization may be predictive of fibrosis. Previously neglected cells including B cells, dendritic cells (DCs), natural killer (NK) cells and natural killer T (NKT) cells were studied more recently for their contribution to sarcoid granuloma formation. Despite these advances, the pathogenesis remains incompletely understood, indicating an urgent need for further research to reveal the distinct immunological events in this process, with hope to open up new therapeutic avenues and if possible, to develop preventive measures.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区:
出版当年[2019]版:
Q1 IMMUNOLOGY
最新[2023]版:
Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2019版] 出版当年五年平均[2015-2019] 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]China Japan Friendship Hosp, Peking Union Med Coll, Ctr Resp Med, Dept Pulm & Crit Care Med, Beijing, Peoples R China
通讯作者:
通讯机构: [3]China Japan Friendship Hosp, Ctr Resp Med, Dept Pulm & Crit Care Med, Beijing, Peoples R China [4]Natl Ctr Resp Med, Beijing, Peoples R China [5]Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China [6]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)